Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

Table 2 Patient-reported EORTC QLQ-C30 scores (subset of patients who provided PRO data)^a

	EU5		*Reference values for advanced breast cancer*^b	*Difference in means (reference value − EU5)*	*Normative values*^c	*Difference in means (normative value − EU5)*
	n	Mean (SD)	*Mean (SD)*	*Difference in means (reference value − EU5)*	*Mean (SD)*	*Difference in means (normative value − EU5)*
Global health/QoL scale	249	50.9 (24.7)	60.2 (25.5)	9.3**	72.3 (20.5)	21.4**
Functional scales
Physical functioning	245	63.5 (24.6)	81.6 (18.7)	18.1**	85.0 (15.9)	21.5**
Role functioning	244	59.9 (27.2)	67.4 (31.1)	7.5**	84.0 (22.4)	24.1**
Emotional functioning	246	61.9 (26.2)	65.9 (24.6)	4.0*	82.5 (18.6)	20.6**
Cognitive functioning	243	66.0 (24.8)	80.5 (23.2)	14.5**	89.7 (15.4)	23.7**
Social functioning	245	65.9 (25.7)	74.2 (28.4)	8.3**	90.6 (18.3)	24.7**
Symptom scales
Fatigue	240	41.1 (24.8)	36.3 (27.0)	−4.8*	22.0 (21.1)	−19.1**
Nausea/vomiting	240	22.4 (24.6)	10.3 (19.7)	−12.1**	3.0 (10.5)	−19.4**
Pain	247	38.7 (27.5)	30.9 (29.6)	−7.8**	24.9 (26.2)	−13.8**
Dyspnea	240	32.6 (32.3)	20.4 (28.2)	−12.2**	12.8 (22.0)	−19.8**
Insomnia	241	36.5 (29.3)	33.1 (32.6)	−3.4	23.8 (26.7)	−12.7**
Appetite loss	244	32.2 (29.1)	21.7 (31.0)	−10.5**	4.7 (13.7)	−27.5**
Constipation	236	22.6 (26.6)	19.2 (28.8)	−3.4	8.3 (17.3)	−14.3**
Diarrhea	241	19.4 (29.4)	5.8 (15.2)	−13.6**	4.7 (14.7)	−14.7**
Financial difficulties	237	22.2 (25.6)	18.6 (28.6)	−3.6	6.3 (16.8)	−15.9**

All scales have a score range of 0–100. For global health/QoL status and functional scales, a higher score represents a better level of functioning/QoL. For symptom scales, a higher score represents worse symptom severity
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30, EU5 European Union 5, HR+/HER2− hormone receptor-positive/human epidermal growth factor receptor 2-negative, PRO patient-reported outcome, QoL quality of life, SD standard deviation
* p < 0.05, ** p ≤ 0.001 (Student’s t-test)
^aScores from the subset of patients with HR+/HER2− advanced breast cancer currently receiving initial endocrine-based therapy for advanced disease who provided PRO data
^bReference values for women (n = 1147, all ages) with recurrent/metastatic breast cancer across all lines of treatment taken from Scott et al. [35]
^cEuropean normative values for women in general population aged 60–69 years from the pooled mean scores of six European normative studies involving 16,151 women and men of all ages, taken from Hinz et al. [36]

ISSN: 1471-2407